Lymphoproliferative disease post-renal transplantation

Nephrology Dialysis Transplantation

Volumn 15, Issue 12, 2000, Pages 1913-1916

  Newstead, Charles G ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; AZATHIOPRINE; B LYMPHOCYTE ANTIBODY; CD20 ANTIGEN; CD24 ANTIGEN; CIDOFOVIR; COMPLEMENT COMPONENT C3D RECEPTOR; CYCLOSPORIN A; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; TACROLIMUS; VALACICLOVIR; VIRUS ANTIBODY; VIRUS DNA;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B LYMPHOCYTE; BLOOD DONOR; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NOTE; PRIORITY JOURNAL; RISK FACTOR; VIRUS INFECTION;

EID: 0033658770     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.12.1913     Document Type: Note

References (25)

1. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients
2. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin steroid therapy
3. A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression
4. Epstein-Barr-virus-induced oncogenesis in immunedeficient individuals
5. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of cytomegalovirus disease
6. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations
7. Confirmation of the heterogeneity of posttransplant Epstein-Barr virus-associated B cell proliferations by immunoglobulin gene rearrangement analyses
8. Classification of the posttransplant lymphoproliferative disorders: From the past to the present
9. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: The role of primary infection
10. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines
11. Dendritic cells transduced with an adenovirus vector encoding epstein-barr virus latent membrane protein 2B: A new modality for vaccination
12. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy
13. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin
14. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders
15. Recurrent Epstein-Barr virus-associated lesions in organ transplant recipients
16. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: Relationships to immunosuppressive therapy, serologic responses and the risk of post-transplant lymphoproliferative disorder
17. Epstein-Barr virus-infected B cells persist in the circulation of acyclovir treated carriers
18. The antiviral prophylaxis of post-transplant lymphoproliferative disorder
19. Lymphoproliferative disorders after organ transplantation in children
20. The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation
21. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
22. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
23. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and-negative lymphoproliferative disorders arising in organ transplant recipients
24. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation
25. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting